Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and catechin

erlotinib hydrochloride has been researched along with catechin in 7 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(catechin)		Trials
(catechin)		Recent Studies (post-2010) (catechin)
4,3537863,03311,5444776,612

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)catechin (IC50)
Arginase Leishmania amazonensis1.7

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's2 (28.57)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Chen, Z'; Khuri, FR; Lee, JE; Shin, DM; Shin, HJ; Tighiouart, M; Yang, CS; Zhang, H; Zhang, X1
Amin, AR; Chen, ZG; Khuri, FR; Shin, DM1
Bigelow, RL; Burke, P; Cardelli, JA; Carroll, JL; Coleman, DT; Milligan, SA; Steffan, JJ; Williams, BJ1
Chen, ZG; Haque, A; Khuri, FR; Rahman, MA; Ruhul Amin, AR; Saba, NF; Shin, DM1
Genç, H; Sinan Özalp, S; Tansu Koparal, A; Tasa, BA; Telli, E1
Galeazzi, R; Laudadio, E; Minnelli, C; Mobbili, G1
Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; El-Deiry, MW; Khuri, FR; Klein, AM; Liu, Y; Nannapaneni, S; Owonikoko, TK; Patel, MR; Ramalingam, SS; Roser, SM; Saba, NF; Shi, Q; Shin, DM; Steuer, CE1

Trials

1 trial(s) available for erlotinib hydrochloride and catechin

ArticleYear
Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 11-15, Volume: 26, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catechin; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Precancerous Conditions; Progression-Free Survival; Protein Kinase Inhibitors; Tea

2020

Other Studies

6 other study(ies) available for erlotinib hydrochloride and catechin

ArticleYear
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Protein-Tyrosine Kinases; Quinazolines; Transplantation, Heterologous

2008
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.
    Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Catechin; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Transcription Factor RelA; Tumor Suppressor Protein p53

2009
The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-01, Volume: 15, Issue:15

    Topics: Animals; Anticarcinogenic Agents; Carcinoma, Non-Small-Cell Lung; Catechin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, SCID; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays

2009
Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.
    Apoptosis : an international journal on programmed cell death, 2015, Volume: 20, Issue:7

    Topics: Anticarcinogenic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Catechin; Cell Line, Tumor; Cycloheximide; Drug Synergism; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Head and Neck Neoplasms; Humans; Membrane Proteins; Phosphorylation; Protein Biosynthesis; Protein Synthesis Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; RNA Interference

2015
In vitro evaluation of combination of EGCG and Erlotinib with classical chemotherapeutics on JAR cells.
    In vitro cellular & developmental biology. Animal, 2017, Volume: 53, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Catechin; Cell Line, Tumor; Choriocarcinoma; Dactinomycin; Enzyme Activation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Receptor, ErbB-2; RNA, Messenger

2017
Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
    International journal of molecular sciences, 2020, Mar-03, Volume: 21, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catechin; Cell Line, Tumor; Cell Membrane; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Docking Simulation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Secondary

2020